Management and prevention of red cell alloimmunization in pregnancy: A systematic review

Obstetrics and Gynecology

Volumn 120, Issue 5, 2012, Pages 1132-1139

  Moise, Kenneth J ^a,b   Argoti, Pedro S ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ALLOIMMUNIZATION; BLOOD VISCOSITY; COCHRANE LIBRARY; DATA BASE; DNA DETERMINATION; EMBASE; ERYTHROCYTE; GENOTYPE; HETEROZYGOSITY; HUMAN; IMMUNOPROPHYLAXIS; INTRAUTERINE BLOOD TRANSFUSION; MEDICAL SUBJECT HEADINGS; MEDLINE; META ANALYSIS; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; PUBLICATION; RED CELL ALLOIMMUNIZATION; RED CELL ISOIMMUNIZATION; REVIEW; RHESUS ALLOIMMUNIZATION; RHESUS INCOMPATIBILITY; RHESUS ISOIMMUNIZATION; RHESUS PROPHYLAXIS; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; ZYGOSITY;

BLOOD TRANSFUSION, INTRAUTERINE; ERYTHROBLASTOSIS, FETAL; ERYTHROCYTES; FEMALE; HUMANS; MIDDLE CEREBRAL ARTERY; PREGNANCY; RH ISOIMMUNIZATION; RHO(D) IMMUNE GLOBULIN;

EID: 84868142445     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31826d7dc1     Document Type: Review

References (39)

1. Zipursky A, Paul VK. The global burden of Rh disease. Arch Dis Child Fetal Neonatal Ed 2011;96:F84-5.
2. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2008;112:164-76.
3. Pirelli KJ, Pietz BC, Johnson ST, Pinder HL, Bellissimo DB. Molecular determination of RHD zygosity: predicting risk of hemolytic disease of the fetus and newborn related to anti-D. Prenat Diagn 2010;30:1207-12.
4. Van den Veyver IB, Moise KJ Jr. Fetal RhD typing by polymerase chain reaction in pregnancies complicated by rhesus alloimmunization. Obstet Gynecol 1996;88:1061-7.
5. Lo YM, Bowell PJ, Selinger M, Mackenzie IZ, Chamberlain P, Gillmer MD, et al. Prenatal determination of fetal RhD status by analysis of peripheral blood of rhesus negative mothers. Lancet 1993;341:1147-8.
6. Faas BH, de Ligt J, Janssen I, Eggink AJ, Wijnberger LD, van Vugt JM, et al. Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells. Expert Opin Biol Ther 2012;12:S19-26.
7. Tynan JA, Mahboubi P, Cagasan LL, van den Boom D, Ehrich M, Oeth P. Restriction enzyme-mediated enhanced detection of circulating cell-free fetal DNA in maternal plasma. J Mol Diagn 2011;13:382-9.
8. Bombard AT, Akolekar R, Farkas DH, VanAgtmael AL, Aguino F, Oeth P, et al. Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women. Prenat Diagn 2011;31:802-8.
9. Mari G, Deter RL, Carpenter RL, Rahman F, Zimmerman R, Moise KJ Jr, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000;342: 9-14.
10. Picklesheimer AH, Oepkes D, Moise KJ Jr, Kush ML, Weiner CP, Harman CR, et al. Determinants of the middle cerebral artery peak systolic velocity in the human fetus. Am J Obstet Gynecol 2007;197:526.e1-4.
11. Divakaran TG, Waugh J, Clark TJ, Khan KS, Whittle MJ, Kilby MD. Noninvasive techniques to detect fetal anemia due to red blood cell alloimmunization: a systematic review. Obstet Gynecol 2001;98:509-17.
12. Oepkes D, Seaward PG, Vandenbussche FP, Windrim R, Kingdom J, Beyene J, et al. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Eng J Med 2006; 355:156-64.
13. Moise KJ Jr. Diagnosing hemolytic disease of the fetus-time to put the needles away? N Engl J Med 2006;355:192-4.
14. Ruma MS, Swartz AE, Kim E, Herring AH, Menard MK, Moise KJ Jr. Angle correction can be used to measure peak systolic velocity in the fetal middle cerebral artery. Am J Obstet Gynecol 2009;200:397.e1-3.
15. Swartz AE, Ruma MS, Kim E, Herring AH, Menard MK, Moise KJ Jr. The effect of fetal heart rate on the peak systolic velocity of the fetal middle cerebral artery. Obstet Gynecol 2009;113:1225-9.
16. Scheier M, Hernandez-Andrade E, Fonseca EB, Nicolaides KH. Prediction of severe fetal anemia in red blood cell alloimmunization after previous intrauterine transfusions. Am J Obstet Gynecol 2006;195:1550-6.
17. Lobato G, Soncini CS. Fetal hydrops and other variables associated with the fetal hematocrit decrease after the first intrauterine transfusion for red cell alloimmunization. Fetal Diagn Ther 2008;24:349-52.
18. Detti L, Oz U, Guney I, Ferguson JE, Bahado-Singh RO, Mari G. Doppler ultrasound velocimetry for timing the second intrauterine transfusion in fetuses with anemia from red cell alloimmunization. Am J Obstet Gynecol 2001;185:1048-51.
19. Yinon Y, Visser J, Kelly EN, Windrim R, Amsalem H, Seaward PG, et al. Early intrauterine transfusion in severe red blood cell alloimmunization. Ultrasound Obstet Gynecol 2010; 36:601-6.
20. Seeho SK, Burton G, Leigh D, Marshall JT, Persson JW, Morris JM. The role of preimplantation genetic diagnosis in the management of severe rhesus alloimmunization: first unaffected pregnancy: case report. Hum Reprod 2005;20:697-701.
21. Fox C, Martin W, Somerset DA, Thompson PJ, Kilby MD. Early intraperitoneal transfusion and adjuvant maternal immunoglobulin therapy in the treatment of severe red cell alloimmunization prior to fetal intravascular transfusion. Fetal Diagn Ther 2008;23:159-63.
22. Ruma MS, Moise KJ Jr, Kim E, Murtha AP, Prutsman WJ, Hassan SS, et al. Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. Am J Obstet Gynecol 2007;196:138.e1-6.
23. Harper DC, Swingle HM, Weiner CP, Bonthius DJ, Aylward GP, Widness JA. Long-term neurodevelopmental outcome and brain volume after treatment for hydrops fetalis by in utero intravascular transfusion. Am J Obstet Gynecol 2006;195: 192-200.
24. Lindenburg IT, Smits-Wintjens VE, van Klink JM, Verduin E, van Kamp IL, Walther FJ, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol 2012;206:141.e1-8.
25. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33.
26. Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther 2010;12:734-40.
27. Hall AM, Cairns LS, Altmann DM, Barker RN, Urbaniak SJ. Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice. Blood 2005;105:2175-9.
28. Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion 1990;30:344-57.
29. Roback JD, Grossman BJ, Harris T, Hillyer CD, eds. Technical manual. 17th ed. Bethesda (MD): AABB; 2011.
30. Ramsey G; College of American Pathologists Transfusion Medicine Resource Committee. Inaccurate doses of R immune globulin after Rh-incompatible fetomaternal hemorrhage: survey of laboratory practice. Arch Pathol Lab Med 2009;133: 465-9.
31. Denomme GA, Wagner FF, Fernandes BJ, Li W, Flegel WA. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion 2005;45:1554-60.
32. Flegel WA. Molecular genetics and clinical applications for Rh. Transfus Apher Sci 2011;44:81-91.
33. Base Rhesus. 2011. Available at: www.uni-ulm.de/;fwagner/RH/RB. Retrieved July 18, 2012.
34. Cannon M, Pierce R, Taber EB, Schucker J. Fatal hydrops fetalis caused by anti-D in a mother with partial D. Obstet Gynecol 2003;102:1143-5.
35. Standards for blood banks and transfusion services. Bethesda (MD): American Association of Blood Banks; 2011.
36. Queenan JT. Rh immunoprophylaxis and fetal RHD genotyping: where are we going? Obstet Gynecol 2012;120:219-20.
37. Wikman AT, Tiblad E, Karlsson A, Olsson ML, Westgren M, Reilly M. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012;120:227-34.
38. Szczepura A, Osipenko L, Freeman K. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregnancy Childbirth 2011;11:5.
39. Management of alloimmunization during pregnancy. Practice Bulletin No. 75. American College of Obstetricians and Gynecologists. Obstet Gynecol 2006;108:457-64.